FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607778312> ?p ?o ?g. }

• W2607778312 abstract "Efavirenz is a widely prescribed medicine used to treat type 1 human immunodeficiency virus (HIV-1), the most prevalent pathogenic strain of the virus responsible for the acquired immune deficiency syndrome (AIDS) pandemic. Under prescribed dosing conditions, either alone or in combination therapy, efavirenz-induced CNS disturbances are frequently reported. Efavirenz was recently reported to interact in a similar concentration range with a number of receptors, transporters and ion channels including recombinant rat α1β2γ2 GABAA receptors whose actions were potentiated (Gatch et al., 2013; Dalwadi et al., 2016). Now we report on the molecular mechanism of efavirenz on GABAA receptors as a function of concentration and subunit composition via whole-cell recordings of GABA-activated currents from HEK293 cells expressing varying subunit configurations of GABAA receptors. Efavirenz elicited dual effects on the GABA response; it allosterically potentiated currents at low concentrations, whereas it inhibited currents at higher concentrations. The allosteric potentiating action on GABAA receptors was pronounced in the α1β2γ2, α2β2γ2 and α4β2γ2 configurations, greatly diminished in the α6β2γ2 configuration, and completely absent in the α3β2γ2 or α5β2γ2 configuration. In stark contrast, the inhibitory modulation of efavirenz at higher concentrations was evident in all subunit configurations examined. Moreover, efavirenz-induced modulatory effects were dependent on GABA concentration ([GABA]), with a pronounced impact on currents activated by low [GABA] but little effect at saturating [GABA]. Mutation of a highly-conserved threonine to phenylalanine in transmembrane domain 2 of the α1 subunit abolished the inhibitory effect of efavirenz in α1β2 receptors. Finally, mutations of any of the three conserved extracellular residues in α1/2/4 subunits to the conserved residues at the corresponding positions in α3/5 subunits (i.e., R84P, M89L or I120L) completely eliminated the potentiating effect of efavirenz in α1β2γ2 configuration. These findings demonstrate that efavirenz's positive allosteric modulation of the GABAA receptor is mediated via a novel allosteric site associated with the extracellular domain of the receptor." @default.
• W2607778312 created "2017-05-05" @default.
• W2607778312 creator A5031892446 @default.
• W2607778312 creator A5047308650 @default.
• W2607778312 creator A5058415430 @default.
• W2607778312 creator A5076963133 @default.
• W2607778312 creator A5090854453 @default.
• W2607778312 date "2017-07-01" @default.
• W2607778312 modified "2023-09-25" @default.
• W2607778312 title "The dual modulatory effects of efavirenz on GABA A receptors are mediated via two distinct sites" @default.
• W2607778312 cites W1482390468 @default.
• W2607778312 cites W1531881786 @default.
• W2607778312 cites W1598979143 @default.
• W2607778312 cites W1805404385 @default.
• W2607778312 cites W1881926654 @default.
• W2607778312 cites W1969068917 @default.
• W2607778312 cites W1972901946 @default.
• W2607778312 cites W1975239375 @default.
• W2607778312 cites W1975711335 @default.
• W2607778312 cites W1976141244 @default.
• W2607778312 cites W1980275705 @default.
• W2607778312 cites W1981625739 @default.
• W2607778312 cites W1982371070 @default.
• W2607778312 cites W1982741440 @default.
• W2607778312 cites W1994264681 @default.
• W2607778312 cites W1995964565 @default.
• W2607778312 cites W2005843451 @default.
• W2607778312 cites W2017518607 @default.
• W2607778312 cites W2022549781 @default.
• W2607778312 cites W2032415987 @default.
• W2607778312 cites W2038477005 @default.
• W2607778312 cites W2044506291 @default.
• W2607778312 cites W2045098707 @default.
• W2607778312 cites W2045120517 @default.
• W2607778312 cites W2050243692 @default.
• W2607778312 cites W2050747932 @default.
• W2607778312 cites W2055351311 @default.
• W2607778312 cites W2073905010 @default.
• W2607778312 cites W2075961210 @default.
• W2607778312 cites W2077244195 @default.
• W2607778312 cites W2079221181 @default.
• W2607778312 cites W2080600913 @default.
• W2607778312 cites W2085409572 @default.
• W2607778312 cites W2086244015 @default.
• W2607778312 cites W2101909919 @default.
• W2607778312 cites W2102903501 @default.
• W2607778312 cites W2122892239 @default.
• W2607778312 cites W2127365733 @default.
• W2607778312 cites W2128383909 @default.
• W2607778312 cites W2136936499 @default.
• W2607778312 cites W2138906086 @default.
• W2607778312 cites W2142437947 @default.
• W2607778312 cites W2143014450 @default.
• W2607778312 cites W2143650619 @default.
• W2607778312 cites W2154379019 @default.
• W2607778312 cites W2163113108 @default.
• W2607778312 cites W2165759090 @default.
• W2607778312 cites W2266553557 @default.
• W2607778312 cites W2313374615 @default.
• W2607778312 cites W2346530763 @default.
• W2607778312 cites W2401756581 @default.
• W2607778312 cites W2407659316 @default.
• W2607778312 cites W2511815093 @default.
• W2607778312 cites W3023841804 @default.
• W2607778312 doi "https://doi.org/10.1016/j.neuropharm.2017.04.038" @default.
• W2607778312 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5512161" @default.
• W2607778312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28456686" @default.
• W2607778312 hasPublicationYear "2017" @default.
• W2607778312 type Work @default.
• W2607778312 sameAs 2607778312 @default.
• W2607778312 citedByCount "5" @default.
• W2607778312 countsByYear W26077783122018 @default.
• W2607778312 countsByYear W26077783122020 @default.
• W2607778312 countsByYear W26077783122021 @default.
• W2607778312 crossrefType "journal-article" @default.
• W2607778312 hasAuthorship W2607778312A5031892446 @default.
• W2607778312 hasAuthorship W2607778312A5047308650 @default.
• W2607778312 hasAuthorship W2607778312A5058415430 @default.
• W2607778312 hasAuthorship W2607778312A5076963133 @default.
• W2607778312 hasAuthorship W2607778312A5090854453 @default.
• W2607778312 hasBestOaLocation W26077783122 @default.
• W2607778312 hasConcept C104292427 @default.
• W2607778312 hasConcept C104317684 @default.
• W2607778312 hasConcept C134018914 @default.
• W2607778312 hasConcept C142462285 @default.
• W2607778312 hasConcept C166342909 @default.
• W2607778312 hasConcept C168258287 @default.
• W2607778312 hasConcept C170493617 @default.
• W2607778312 hasConcept C17077164 @default.
• W2607778312 hasConcept C185592680 @default.
• W2607778312 hasConcept C203014093 @default.
• W2607778312 hasConcept C2522874641 @default.
• W2607778312 hasConcept C2781432083 @default.
• W2607778312 hasConcept C2993143319 @default.
• W2607778312 hasConcept C55493867 @default.
• W2607778312 hasConcept C86803240 @default.
• W2607778312 hasConcept C9224880 @default.
• W2607778312 hasConcept C98274493 @default.
• W2607778312 hasConceptScore W2607778312C104292427 @default.
• W2607778312 hasConceptScore W2607778312C104317684 @default.

• next